Phase 2Active, not recruiting
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
- Sponsor
- Memorial Sloan Kettering Cancer Center (Academic or other)
- Enrolment
- 292 enrolled
- Conditions
- Appendix Cancer; Colorectal Cancer
- Interventions
- Cytoreductive Surgery; HIPEC with Mitomycin-C; EPIC with FUDR and Leucovorin
- Ages
- adults, older adults
- Registry
- NCT01815359
Full record on ClinicalTrials.gov
From the registry
This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.
Primary outcomes
- disease-free survival
History
Primary completion expected
Last registry update
Registered
Started